Stereotaxis has completed its previously announced acquisition of Robocath in a deal valued at up to $45 million, strengthening its position in the endovascular robotics market.
The transaction includes an upfront payment of $20 million, with up to $25 million in milestone-based payments tied to regulatory and commercial achievements, including FDA clearance of Robocath’s next-generation robotic platform.
Related: Boustead acquires majority stake in urology robotics company UroMedTech
Robocath develops robotic systems for interventional cardiology and neurointerventions, including its CE-marked R-One platform. Stereotaxis plans to integrate Robocath’s mechanical robotics technology with its magnetic navigation systems to accelerate the development of robotic solutions for electrophysiology, interventional cardiology, and neurointerventions.
CEO David Fischel said:
“The addition of Robocath’s technology and team to Stereotaxis accelerates our strategy, enhances our technological leadership, provides attractive commercial synergies in an expanded addressable market, and supports new strategic opportunities.”
The acquisition expands Stereotaxis’ robotic surgery portfolio and supports its strategy to develop fully robotic endovascular platforms for minimally invasive procedures.
